Drug Type TCR-T Cell therapy |
Synonyms ENGI-003 specTR(Engimmune Therapeutics), ENGI 003, ENGI003 |
Target |
Action inhibitors |
Mechanism GPC3 inhibitors(Glypican-3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatocellular Carcinoma | Preclinical | Switzerland | 01 Oct 2024 |